Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors

NCT00688623 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00688623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00688623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 24, 2009
Completion date
November 7, 2016
Enrollment
73 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and metastatic silent neuro-endocrine tumors, carcinoids, carcinoma, neuroendocrine, non functioning, non functioning neuroendocrine tumors (nets), non syndromic neuroendocrine tumors